G1 Therapeutics Inc. (NASDAQ:GTHX) finished Friday with a subtraction of -$0.05 to close at $1.96, a downside of -2.49 percent. An average of 1,267,820 shares of common stock have been traded in the last five days. There was a fall of -$0.21 in the past week, and it reached a new high 13 times over the past 12 months. The last 20 days have seen an average of 1,555,630 shares traded, while the 50-day average volume stands at 1,032,924.
GTHX stock has decreased by -19.34% in the last month. The company shares reached their 1-month lowest point of $1.95 on 08/11/23. With the stock rallying to its 52-week high on 02/02/23, shares of the company touched a low of $1.97 and a high of $17.49 in 52 weeks. It has reached a new high 10 times so far this year and lost -63.90% or -$3.47 in price. In spite of this, the price is down -88.79% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
GTHX stock investors should be aware that G1 Therapeutics Inc. (GTHX) stock had its last reported insider trading activity 4 days ago on Aug 08. In this transaction, the insider spent $119,974. President and CEO, Bailey John E. (Jack) Jr., disposed of 2,719 shares at a price of $2.45 on Jul 05. The insider now owns more than $6,672 worth of shares. Prior to that, Chief Operating Officer MURDOCK TERRY L went on to Sale 1,361 shares at $2.45 each on Jul 05. An amount of $3,339 was transacted.
Valuation Metrics
G1 Therapeutics Inc. (GTHX) stock’s beta is 1.85. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.82, the price-to-book (PB) ratio at 1.77.
Financial Health
The quick ratio of G1 Therapeutics Inc. for the three months ended June 29 was 3.70, and the current ratio was 4.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.89 and a total debt to equity ratio of 0.89 for the quarter ending June 29. G1 Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -264.42%. Its gross profit as reported stood at $47.55 million compared to revenue of $51.3 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, G1 Therapeutics Inc.’s return on assets was -46.80%.
Earnings Surprise
For the three-month period that ended June 29, G1 Therapeutics Inc. had $48.32 million in cash and short-term investments compared to $50.94 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $8.71 million in the quarter, while revenues of -$27.6 million were grew 552.93%. The analyst consensus anticipated G1 Therapeutics Inc.’s latest quarter earnings to come in at -$0.22 per share, but it turned out to be $0.14, a 163.60% surprise. For the quarter, EBITDA amounted to $11.95 million. Shareholders own equity worth $51.75 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at G1 Therapeutics Inc. (GTHX) price momentum. RSI 9-day as of the close on 11 August was 24.11%, suggesting the stock is oversold, with historical volatility in this time frame at 56.56%.
As of today, GTHX’s price is $2.01 -9.68% or -$0.21 from its 5-day moving average. GTHX is currently trading -18.67% lower than its 20-day SMA and -33.33% lower than its 100-day SMA. However, the stock’s current price level is -22.83% below the SMA50 and -82.20% below the SMA200.
The stochastic %K and %D were 5.96% and 6.74%, respectively, and the average true range (ATR) was 0.12. With the 14-day stochastic at 2.00% and the average true range at 0.12, the RSI (14) stands at 28.69%. The stock has reached -0.09 on the 9-day MACD Oscillator while the 14-day reading was at -0.19.
Analyst Ratings
JP Morgan upgraded G1 Therapeutics Inc. (NASDAQ: GTHX) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as an Underweight. The consensus rating for G1 Therapeutics Inc. (GTHX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell GTHX, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 6 others rate it as a “buy”.
What is GTHX’s price target for the next 12 months?
Analysts predict a range of price targets between $5.00 and $19.00, with a median target of $9.50. Taking a look at these predictions, the average price target given by analysts for G1 Therapeutics Inc. (GTHX) stock is $10.50.
